Last Updated on March 15, 2025 by The Health Master
Testing Laboratories
The landscape of pharmaceutical regulation in India is undergoing a significant shift, with the Drugs Controller General of India (DCGI), Dr. Rajeev Singh Raghuvanshi, spearheading initiatives to bolster drug safety and uniformity.
Recognizing the strain on central testing laboratories, the DCGI has issued a crucial directive: state licensing authorities (SLAs) must fortify their testing capabilities.
This move, coupled with the development of a State Drug Regulatory Index, signals a comprehensive overhaul of the nation’s drug regulatory framework.
Strengthening State Testing Laboratories: A Necessity, Not an Option
Dr. Raghuvanshi’s call to action stems from the sheer volume of samples inundating central laboratories.
“Central laboratories are already fully occupied,” he emphasized during a recent Drugs Consultative Committee (DCC) meeting.
This backlog risks delays in critical testing, potentially compromising public health.
To alleviate this burden, SLAs are now tasked with enhancing their state testing laboratories.
This means investing in cutting-edge equipment, training personnel, and streamlining testing procedures.
Key Focus:
- Increased sample processing capacity.
- Improved accuracy and reliability of test results.
- Faster turnaround times.
Why This Matters:
- Ensures timely detection of substandard or counterfeit drugs.
- Safeguards public health by maintaining drug quality.
- Reduces reliance on central laboratories, promoting efficiency.
This also helps in the pharmaceutical quality control jobs sector, as more skilled workers will be needed.
A Unified Approach
Beyond bolstering testing infrastructure, the DCGI is championing the creation of a State Drug Regulatory Index.
This initiative aims to harmonize drug regulatory standards across India, which are currently managed by individual state governments.
This index will promote:
- Enhanced Drug Safety Surveillance: By establishing clear metrics and monitoring mechanisms.
- Promoting Accountability: By tracking and evaluating the performance of SLAs.
- Fostering Collaboration: By creating a platform for knowledge sharing and best practices.
- Enhancing Resource Utilization: By optimizing the allocation of resources and infrastructure.
- Inclusion of Enforcement Activities: The DCC has recommended that the index include parameters such as the number of raids conducted, making the index more robust.
- This will help in regulatory compliance consulting services.
Risk-Based Inspections: Focusing on Critical Products
The DCGI also underscored the importance of regular inspections, particularly for facilities manufacturing complex and critical products like:
- Large volume parenterals,
- Small volume parenterals,
- Vaccines, and
- r-DNA products.
A risk-based approach will prioritize inspections based on the potential impact on public health.
Key Products Targeted:
- Large volume parenterals.
- Small volume parenterals.
- Vaccines.
- r-DNA products.
Why Risk-Based Inspections?
- Maximizes the effectiveness of inspections.
- Focuses resources on high-risk areas.
- Ensures the quality and safety of critical medications.
Financial Backing and Future Outlook
The Department of Pharmaceuticals, through the Centrally Sponsored Scheme of Strengthening of States Drug Regulatory System (SSDRS), has been providing financial support to states for enhancing their regulatory infrastructure.
While the budget allocation for the scheme has seen fluctuations, the commitment to strengthening the drug regulatory system remains strong.
SSDRS Funding:
- Total outlay: Rs. 1,750 crore (with Rs. 850 crore for SSDRS).
- FY25-26 budget estimate: Rs. 50 crore.
Boosting Participation and Uniformity
The DCGI has also called for greater participation from SLAs in DCC meetings, emphasizing the need for timely submission of agenda items to ensure uniformity in the administration of the Drugs and Cosmetics Act.
Q. What is the purpose of the State Drug Regulatory Index?
A. To ensure uniformity and effectiveness in drug regulation across all states and union territories in India.
Q. Why is the DCGI emphasizing state testing laboratories?
A. To alleviate the burden on central laboratories and ensure timely testing of drug samples.
Q. What types of manufacturing facilities will be prioritized for inspections?
A. Facilities manufacturing complex and critical products like vaccines and parenterals.
Q. What is the importance of a risk-based approach to manufacturing inspection?
A. It allows for the focusing of resources on the most important high-risk areas.
Disclaimer: This article contains information obtained from the source mentioned below. Our team made changes in the format to rewrite and present the news or article in a unique format.
Laboratory Waste Management, Types and Its Disposal
NABL certification procedure for Laboratories
Quality Assurance Vs Quality Control in the Pharma Industry
NABL certification for Laboratories: Let’s understand
Major FDA audit findings about Equipment and Instruments
Equipment and Instruments: Maintenance, difference and importance in the Pharma Industry
Upcoming events: Pharma, Cosmetics, Homoeopathy & Medical Devices
Cosmetics Testing in India: A Comprehensive Guide
Difference between Validation and Calibration in the Pharma Industry
Calibration of Laboratory Instruments
Difference: Disintegration and Dissolution test in pharma industry
Understanding DQ, IQ, PQ, and OQ in the Pharma Industry
Duties and responsibilities of QA person in Pharma Industry
Dissolution test: Importance in Pharma Industry
USFDA issues Warning Letter to Granules India over these Deficiencies
CM Haryana Honors FDA Haryana Team
CDSCO approval granted for Durvalumab for Limited-Stage SCLC in India
USFDA issues warning letter to Dexcom for 2 facilities
DCA Telangana cracks down on distributors for Storage Violations
USFDA issued Form 483 to Alembic Pharma with 1 observation
NPPA fixed retail price of 53 formulations: March 2025
DCC agrees with proposal to amend Rule 89 for better clarity
Gujarat Drug Inspectors Armed with Spectrophotometers for Instant Drug Tests
